Innovative Biomaterials and Biomarker Technologies: Advancing Cancer Diagnosis and Therapeutic Applications in Medicine The crucial role of cutting-edge biomaterials and biomarkers in revolutionizing cancer treatment lies in their ability to enhance precision and effectiveness in various therapeutic approaches. This field focuses on developing advanced biomaterials such as nanocarriers, hydrogels, and biodegradable polymers that enhance targeted drug delivery, tissue engineering, and localized therapy. Additionally, biomarkers are integral for early cancer detection, guiding precision medicine, and improving immunotherapy outcomes. The integration of technologies like 3D bioprinting and wearable biosensors offers promising advancements in tumor modeling, personalized treatment, and real-time monitoring. Overall, the advanced biomaterials and biomarker technologies underscores the significant impact of these innovations in enhancing cancer diagnosis and therapeutic strategies.   Potential topics include but are not limited to: -Smart nanocarriers for precision oncology: biomaterial-based approaches -Advances in biomarker-guided immunotherapy for cancer treatment -Biodegradable nanoparticles in chemotherapy for sustained drug release -Biomaterial scaffolds for tumor microenvironment modulation -Exosome-derived biomarkers: new frontiers in cancer diagnosis -Hydrogel-based drug delivery systems for targeted cancer therapy -Wearable biosensors for real-time monitoring of cancer biomarkers   Guest Editor Xiangli Shao  Department of Chemistry, University of Texas at Austin, Austin, TX 78712, USA Interests: Nano materials-based biosensors; Functional nucleic acids-based biosensors; Biosensors for medical diagnosis, imaging, and therapy Biomaterials in radiotherapy: enhancing targeted treatment of cancer cells   Submission Deadline:  22 April 2025

The IV Eurasian (Russian-Chinese) Congress is planned to be held on November 27-28, 2024 in the city of Ufa on the treatment of cardiovascular diseases (hereinafter referred to as the Congress) with the participation of leading cardiologists, scientists, cardiovascular surgeons, therapists, general practitioners, intensive care, diagnostics specialists, etc. The events of the Congress will contribute to closer international cooperation on current issues of cardiology, the exchange of accumulated experience in the formation and promotion of healthy lifestyle priorities, prolongation of active longevity, further development and improvement of the quality of specialized, including high-tech medical care for the population, as well as advanced training of cardiologists, cardiovascular surgeons, therapists, general practitioners, doctors of other related specialties. At the Congress, current issues of the most important aspects of specialized cardiology provision, consolidation of expert and scientific potential in the field of provision of specialized cardiac care, and creation of effective programs for the prevention of cardiovascular diseases will be considered.  During the Congress, the live surgery/arrhythmological intervention cases will be presented, as well as the young investigators' section and basic science sections.  The participation of specialists from the Russian Federation, CIS countries, and abroad is expected. Among the Russian participants, there are main experts from the Republics, territories, and regions on the topics of the Congress. As part of the Congress, an exhibition of achievements of the domestic and foreign medical industry will be organized. Congress venue: “Congress Hall Toratau”, 450076, Republic of Bashkortostan, Ufa, Zaki Validi st., 2. Dates:  November 27-28, 2024. Form of participation: online/offline participation in the scientific and educational program, reports. Contact numbers: Khusainova Elina Maratovna omorkd@mail.ru; +79174747116, Kovrigina Natalya Filaretovna, tntufa@inbox.ru; +79173440813, Dr. Naufal Zagidullin, +79625467622, znaufal@mail.ru (international guests)

Global Translational Medicine (GTM) is a quarterly journal that focuses on medicine, biological sciences, and biomaterials engineering. The goal of Global Translational Medicine is to provide a platform for researchers to showcase their latest research works in translational medicine so as to advance the field towards the betterment of human health. Despite the advancement of omics and new technologies, the process of transforming these technologies and scientific research results into effective therapies and putting them into clinical use still has a long way to go. Global Translational Medicine provides a platform to fill the gaps in preclinical and inter-disciplinary research, promote clinical translation of scientific research results, and contribute to the conception of new and improved preventive measures as well as diagnostic and therapeutic techniques of diseases. Global Translational Medicine covers subject areas, including but not limited to the following: cardiovascular disease metabolism/diabetes/obesity neuroscience/neurology cancer biomaterials and their applications in medicine proteomics/metabolomics pharmacogenomics biomarkers bioinformatics and data mining animal and clinical research, and medical methods arising from interdisciplinary crossover We welcome researchers and scholars in related fields to submit manuscripts to GTM. GTM upholds high publishing standards and adheres to rigorous peer review prior to acceptance. Potential authors are encouraged to make submissions through the online submission system： https://accscience.com/user/login  If you have any questions about submissions and publications, please contact the Editorial Office at gtm.office@accscience.sg Warm Regards,Editorial OfficeGlobal Translational Medicine AccScience Publishinggtm.office@accscience.sg

We extend our sincere congratulations to the 8 Editorial Board Members of GTM who have been recognized as Highly Cited Researchers for the year 2023 by Clarivate. They are being recognized for their high-quality scientific research achievements and outstanding contributions to their professional fields, as indicated by Web of Science data. Congratulations to the scholars for their noteworthy achievement – we are honored to have them on board with our journal! Source: https://clarivate.com/highly-cited-researchers/ FULL NAME CATEGORY PRIMARY AFFILIATION SECONDARY AFFILIATIONS Arai, Hidenori Cross-Field National Center for Geriatrics & Gerontology, Japan   Guo, Shaojun Materials Science Peking University, China Mainland   Kamal, Mohammad Amiad Cross-Field King Abdulaziz University, Saudi Arabia   Kovatcheva-Datchary, Petia Cross-Field University of Gothenburg, Sweden   Kristiansen, Karsten Microbiology University of Copenhagen, Denmark Beijing Genomics Institute (BGl), Peoples R China Lusis, Aldons J. Molecular Biology and Genetics David Geffen School of Medicine at UCLA, United States   Zhang, Yu-Dong Cross-Field King Abdulaziz University, Saudi Arabia University of Leicester, United Kingdom Wang, Zeneng Cross-Field Cleveland Clinic Foundation, United States    

We are pleased to announce that Global Translational Medicine (GTM, Online ISSN: 2811-0021, Publisher: AccScience Publishing) has been listed as a journal that follows the editorial recommendations of the International Committee of Medical Journal Editors (ICMJE) on November 17, 2023 (http://icmje.acponline.org/journals-following-the-icmje-recommendations/). The ICMJE is a small working group of general medical journal editors and representatives of selected related organizations working together to improve the quality of medical science and its reporting. In November 2023, under the application of GTM, the ICMJE listed GTM as a journal that follows the ICMJE's Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. This gave us great encouragement and confidence to develop GTM as a premier, desirable, and transparent international platform for the dissemination of state-of-the-art basic, translational, and clinical medcine studies. As an academic publishing platform, GTM will continuously comply with the guidelines of Committee on Publication Ethics (COPE), World Association of Medical Editors (WAME), and ICMJE, and endeavor to publish more valuable and scientific research findings to promote scientific innovation.

On August 18, 2023, Global Translational Medicine (GTM, Online ISSN: 2811-0021) had been included in the esteemed database, Chemical Abstracts Service (CAS). This achievement stands as a significant milestone for our journal since its inception in 2022, signifying a remarkable acknowledgment of GTM within the global academic community. The CAS database is founded in 1907 as a volunteer effort to organize published chemistry research, CAS officially became a self-supporting division of the American Chemical Society in 1956. CAS is widely acknowledged as the most comprehensive and authoritative source of chemical and scientific research. CAS provides access to over 150 million records from over 100 countries, including patents, scientific articles, and conference proceedings. Please click here to learn more about CAS: https://www.cas.org/. The editorial team at GTM extends heartfelt gratitude to all esteemed members of the editorial board whose contributions have been instrumental in steering the journal's growth. We extend our appreciation to authors, reviewers, and readers alike for their unwavering support and profound engagement with the journal. Our pledge to provide a valuable platform for groundbreaking Translational Medicine remains unwavering, underscored by our dedication to upholding the highest standards of publishing integrity. It is our aspiration to ascend as a premier international academic journal. GTM will continue to uphold rigorous academic standards while publishing more high-quality articles, thereby improving our academic eminence and impact. These efforts are aimed at making greater contributions to academic research and technological innovation.